ObsEva
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Chemin Des Aulx 12, Plan-les-Ouates, Gen...Phone Number
+41 225523840Website
www.obseva.comRevenue
$19.6 MillionStock Symbol
OBSVIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labour. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is traded under the ticker symbol "OBSN".Explore more
Popular SearchesObsEvaObseva SAObseva Usa IncObsEva'SAObsEva.comSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: OBSVShow moreObsEva Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ObsEva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on ObsEva recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if ObsEva is spiking on competitors!
Click to see if ObsEva had a recent Job posting/layoffs
Check if ObsEva has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when ObsEva launches new products
Funding: Get notified immidiatlly once ObsEva has new funding data
ObsEva, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at ObsEva
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
ObsEva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ObsEva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ObsEva.
ObsEva financials insights
Gather financial insights about ObsEva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Stock Offering
$96.8M
ObsEva Tech Stack
A closer look at the technologies used by ObsEva
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
ObsEva News & Media
ObsEva Announces Update on Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeWomen's health company Obseva to wind down, lay off staff | BioPharma Dive
The company is still attempting to “monetize” its most advanced drug, a treatment to aid pregnancy via in vitro fertilization.ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeGeneva Court Grants Temporary Moratorium to ObsEva
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Read more news
Top Manufacturing Companies
Frequently Asked Questions Regarding ObsEva
Sign Up For FreeTo access detailed company insights
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, en... Read More
